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As the life expectancy is improving, the risk of both 
cardiovascular disease and cancer is increasing. Cancer 
and cardiovascular disease are the leading causes of 
morbidity and mortality worldwide. Therefore, it is no 
surprise that most cancer centres are now inundated with 
an ageing population of cancer patients who also have 
multiple cardiac issues. Over the past few decades, there 
has been significant improvement in the quality of life 
and survival of cancer patients due to the introduction 
of newer therapies. Chemotherapy seems to have been 
pushed to the backstage, with targeted therapy now in 
the forefront. Advances in molecular therapy monoclonal 
antibodies and immunotherapy are changing the landscape 
for cancer patients. As the life expectancy is improving 
due to advances in cardiovascular medicine, the incidence 
of cancer is rising in the ageing population.
It is important to note the fact that both cancer and 
cardiovascular disease have somewhat shared origins. The 
major cardiovascular risk factors such as obesity cigarette 
smoking poor dietary habits lack of exercise alcoholism 
and increasing age are shared by both disease entities. 
Similarly, due to the intense nature of cancer therapy, 
patients on active treatment tend to develop unhealthy 
lifestyles including physical inactivity excessive weight 
loss or weight gain high levels of stress and anxiety, all 
of which enhance the risk of cardiovascular morbidity 
and mortality.
Cancer therapy associated cardiotoxicity is a well-known 
phenomenon. Association between anthracycline use and 
cardiotoxicity was identified almost five decades ago.[1] 
Cardiovascular mortality has been reported as the main 
cause of mortality 10 years after the diagnosis of breast 
cancer.[2] Over the years, however, the development of 
new targeted therapies has resulted in a wide variety of 
cardiac problems. The term ‘cancer therapeutics related 
cardiac dysfunction’ has been used to define the potential 
cardiotoxicity in such instances.[3] This knowledge has 
certainly led to better outcomes and has given rise to a 
novel cardiology subspecialty known as cardio-oncology, 
with the international cardiology oncology society having 
been established in 2009.
Cardiotoxicity may be attributed to the direct effect of 
cancer therapy on the heart, but it could also be due to the 
development or unmasking of underlying cardiovascular 
diseases in cancer patients. Within the speciality of 
cardio-oncology, years of research and clinical practice 
have given birth to the multiple hit hypothesis, which 
was first described in 2007.[4] This hypothesis proposes 
that patients with cancer are exposed to a series of 
sequential or concurrent events that together make them 
more vulnerable to reduced cardiovascular reserves the 
development of incidental cardiovascular disease and 
eventually death.
Cardiotoxicity can be of various types. Since most cancer 
centres have a large volume of breast cancer and lymphoma 
patients, anthracycline-associated cardiotoxicity has been 
the most frequently encountered problem in the past. 
Other than anthracycline agents such as trastuzumab 
cyclophosphamide and tyrosine kinase inhibitors have 
been shown to cause left ventricular dysfunction. While 
anthracycline-induced cardiotoxicity is permanent due 
to destruction of myocytes, trastuzumab-associated 
dysfunction is usually reversible.[5,6] Hypertension is also a 
well-known sequela of treatment with vascular endothelial 
growth factor inhibitors such as bevacizumab sorafenib 
sunitinib and also erythropoietin-stimulating agents.[7,8] 
Certain drugshave been implicated in predisposition to 
cardiac arrhythmias such as atrial fibrillation and QT interval 
prolongation. Medications used for supportive care in cancer 
patients such as antiemetics antidepressants antihistamines 
and antipsychotics can also lead to cardiac conduction 
disturbances. Chemotherapy drugs like 5-fluorouracil have 
a well-known association with coronary vasospasm and 
angina-like symptoms. Proteasome inhibitors have also 
been implicated in cardiac morbidity. More recently, the 
use of checkpoint inhibitor therapy has resulted in rare, but 
serious cardiotoxicity including myocarditis cardiac arrest 
and maybe even myocardial fibrosis.[9] Radiation treatment, 
which is often employed in cancer treatment, can also lead 
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to accelerated atherosclerosis pericardial inflammation or 
damage to the heart valves.[10]
Given the myriad of cardiac issues associated with 
cancer treatments, it is very important to establish 
cardio-oncology services in large volume cancer centres. 
Knowledge of the adverse effects of cancer therapy on 
the heart balanced with knowledge of the natural history 
of malignancy offers an opportunity to provide effective 
care to the cancer patients. The cardio-oncology team is 
a multidisciplinary team of professionals who provide 
care with a special focus on cardiovascular disease. Such 
a team comprises medical and radiation oncologists 
haematologists cardiologists and specialised nurses. 
Supporting members may include hospitalists surgeons 
pathologists radiologists pharmacists psychologists 
social workers and members of the palliative care team. 
The medical oncologists are expected to refer patients to 
the cardiology clinic in a timely fashion. The role of the 
cardiologist is to facilitate cancer treatment.
Large volume cancer centres in the United States have set 
up cardio-oncology clinics with the goal of facilitating 
the diagnosis and therapy of cancer treatment-related 
cardiovascular complications. One of the reputable 
centres in the United States initially utilized a computer-
based consultation system, and later, face-to-face 
clinical encounters were set up for cancer patients 
needing dedicated cardiac care. Educational sessions 
for both health-care staff and patients were set up. This 
clinic witnessed healthy growth over a short period of 
time, with promising results expected in the long run. 
Interdisciplinary communication was found to be essential 
for the effective operation of this cardio-oncology unit.[11]
In the day-to-day functioning of the cardio-oncology 
unit, it is imperative to identify individuals who are 
at high risk for cardiotoxicity, such as those with poor 
lifestyle habits, or comorbidities such as hypertension 
coronary artery disease and diabetes. This screening 
includes not only patients who are receiving potentially 
cardiotoxic chemotherapy but also those who are to 
undergo any cancer-related surgery. Such patients should 
have baseline blood pressure measurement along with 
an electrocardiogram or echocardiogram as deemed 
appropriate. Baseline assessment of QT interval is relevant 
in certain patients. Similarly, an echocardiogram is 
essential for those who will be subjected to anthracyclines 
or Her-2 targeted therapy. As we know from prior studies, 
there is a sudden rise in the probability of heart failure 
once the cumulative dose of anthracycline exceeds 
400 mg/m2. There are no sensitive echocardiographic 
techniques such as strain imaging that can detect subtle 
left ventricular dysfunction. For example, a decrease in 
the global longitudinal strain of >15% from baseline is a 
sign of early cardiotoxicity.[12] Similarly, biomarkers such 
as plasma troponin concentration or B-type natriuretic 
peptide can be used as indicators of early cardiotoxicity.[13]
Once baseline evaluation has been performed, 
patients should have active surveillance of their 
cardiovascular health during the treatment. This includes 
echocardiography, cardiac MRI, or any other pertinent 
studies. Any changes in cardiovascular status should 
immediately prompt the team to reevaluate the patient’s 
treatment plan. The need for cardioprotective medical 
therapy, for example, the use of dexrazoxane to combat 
anthracycline-mediated cardiotoxicity or the use of 
beta-blockers angiotensin-converting enzyme inhibitors 
or statins in patients with a subclinical drop in ejection 
fraction should be considered on a case-by-case basis.[13,14]
Once a cardio-oncology clinic has been set up, audits can 
be conducted from time to time to test the efficiency of 
the system and to make sure that there are no unnecessary 
delays in the process of referral. Computer software 
can be used to maintain a separate database of such 
patients. Finally, collection of patient feedback through 
questionnaires or surveys is helpful in identifying any 
weaknesses and deficiencies in the program.[15]
In conclusion, it should be a top priority of oncologists 
and haematologists to work in conjunction with their 
cardiology colleagues to evaluate the cardiovascular 
health of their patients and to address the potential 
cardiotoxicity associated with cancer therapy. Setting up 
a cardio-oncology program seems to be the best way to 
achieve this objective. Comprehensive cancer centres in 
the United States and Europe have now set up dedicated 
cardio-oncology clinics, and many other centres are now 
following suit. The creation of such a partnership will 
undoubtedly lead to a high-quality medical practice and 
will ensure the provision of multidisciplinary care to our 
cancer patients.
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